Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis

Tuberculosis treatment is shortened to six months by the indispensable addition of pyrazinamide (PZA) to the drug regimen that includes isoniazid and rifampin. PZA is a pro-drug of pyrazinoic acid (POA) (ref. 3), whose target of action has never been identified. Although PZA is active only against Mycobacterium tuberculosis, the PZA analog 5-chloro-pyrazinamide (5-Cl-PZA) displays a broader range of anti-mycobacterial activity. We have found that the eukaryotic-like fas1 gene (encoding fatty acid synthetase I, FASI) from M. avium, M. bovis BCG or M. tuberculosis confers resistance to 5-Cl-PZA when present on multi-copy vectors in M. smegmatis. 5-Cl-PZA and PZA markedly inhibited the activity of M. tuberculosis FASI, the biosynthesis of C16 to C24/C26 fatty acids from acetyl-CoA (ref. 6). Importantly, PZA inhibited FASI in M. tuberculosis in correlation with PZA susceptibility. These results indicate that FASI is a primary target of action for PZA in M. tuberculosis. Further characterization of FASI as a drug target for PZA may allow the development of new drugs to shorten the therapy against M. tuberculosis and may provide more options for treatment against M. bovis, M. avium and drug resistant M. tuberculosis.

[1]  J. Grosset.  The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. , 1978, Bulletin of the International Union against Tuberculosis.

[2]  A. Azad,et al.  Biochemistry and molecular genetics of cell‐wall lipid biosynthesis in mycobacteria , 1997, Molecular microbiology.

[3]  H. Nikaido,et al.  Role of Acid pH and Deficient Efflux of Pyrazinoic Acid in Unique Susceptibility of Mycobacterium tuberculosis to Pyrazinamide , 1999, Journal of bacteriology.

[4]  J. Batten.  Experimental chemotherapy of tuberculosis. , 1968, British medical journal.

[5]  D. Mitchison.  The action of antituberculosis drugs in short-course chemotherapy. , 1985, Tubercle.

[6]  W. Mcdermott,et al.  Activation of pyrazinamide and nicotinamide in acidic environments in vitro. , 1954, American review of tuberculosis.

[7]  K. Bloch.  [10] Fatty acid synthases from Mycobacterium phlei , 1975 .

[8]  J. H. Williams,et al.  Experimental Chemotherapy of Tuberculosis. II. The Synthesis of Pyrazinamides and Related Compounds1 , 1952 .

[9]  R. J. Anderson.  THE CHEMISTRY OF THE LIPOIDS OF TUBERCLE BACILLI VIII. CONCERNING THE UNSAPONIFIABLE WAX , 1929 .

[10]  P. Kolattukudy,et al.  Cloning, sequencing and characterization of a fatty acid synthase-encoding gene from Mycobacterium tuberculosis var. bovis BCG. , 1996, Gene.

[11]  L. Reller,et al.  Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system. , 1990, The Journal of infectious diseases.

[12]  K. Bloch.  Fatty acid synthases from Mycobacterium phlei. , 1975, Methods in enzymology.

[13]  K. Bergmann,et al.  Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity. , 1995, Journal of medicinal chemistry.

[14]  A. Telenti,et al.  The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol , 1997, Nature Medicine.

[15]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[16]  Ying Zhang,et al.  Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus , 1996, Nature Medicine.

[17]  M. A. Steele,et al.  The role of pyrazinamide in tuberculosis chemotherapy. , 1988, Chest.

[18]  B. Plikaytis,et al.  Identification and drug susceptibility test results for Mycobacterium spp. , 1985 .

[19]  M. E. Villarino.  Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations , 1998 .

[20]  S. Kikuchi,et al.  Purification and characterization of an unusually large fatty acid synthase from Mycobacterium tuberculosis var. bovis BCG. , 1992, Archives of biochemistry and biophysics.

[21]  M. G. Carlson,et al.  Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[22]  M. Cynamon,et al.  In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide , 1998, Antimicrobial Agents and Chemotherapy.

[23]  W. Mcdermott,et al.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli. , 1967, The American review of respiratory disease.

[24]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[25]  G. Besra,et al.  Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis , 1996, Antimicrobial agents and chemotherapy.

[26]  J. Thompson,et al.  Analysis of mycolic acids by high-performance liquid chromatography and fluorimetric detection. Implications for the identification of mycobacteria in clinical samples. , 1995, Journal of chromatography. A.

[27]  W. Mcdermott,et al.  THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUE , 1956, The Journal of experimental medicine.

[28]  K. Bloch,et al.  Mycobacterium phlei Fatty Acid Synthetase—A Bacterial Multienzyme Complex , 1969, Nature.

[29]  R. J. Anderson,et al.  Chemistry of the Lipoids of Tubercle Bacilli , 1930 .

[30]  David A. Mead,et al.  Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP synthase by isoniazid , 1998 .

[31]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[32]  R. Gilman,et al.  Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis , 1997, Antimicrobial agents and chemotherapy.

[33]  E. L. Armstrong,et al.  Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. , 1975, Journal of lipid research.

[34]  Pulmonary Infections.  Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children , 1998 .

[35]  D. Snider,et al.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. , 1994, American journal of respiratory and critical care medicine.